This year’s ISPE Annual Meeting & Expo will be full of great, thought-provoking content for the Investigational Products Community of Practice.
The theme “Driving Innovation to Advance Patient Therapies” aligns with the Investigational Products track focused on supply chain agility. From driving efficiency in demand modeling through agility in distribution, the topics will invoke discussion amongst Investigation Products professionals as to how we can innovate to meet the demands of the future.
The End to End Supply Chain Management track kicks off on Sunday with the session “Artificial Intelligence: Taking the Mystery Out of Supply Chain Planning”. This session will be followed by a discussion on how to “Leverage Expiry Date Material Planning to Reduce Waste.” Additional sessions that will be featured during the End-to-End Supply Chain Management track include:
We look forward to seeing and networking with all of you at our annual Investigational Products Community of Practice event on Monday Night. It promises to be an exciting evening of Halloween fun as we cruise on a casino game ship reuniting old acquaintances and meeting new ones to continue to strengthen our community.
To learn more about the 2017 ISPE Annual Meeting & Expo and the End-to-End Supply Chain Management sessions offered during the conference, visit the conference website.
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...